Page last updated: 2024-12-09

1,3-diphenyl-4-pyrazolecarbonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1,3-diphenyl-4-pyrazolecarbonitrile is an organic compound with the molecular formula C16H11N3. It is a white solid that is soluble in organic solvents. This compound is important for research because of its potential applications in several fields:

**1. Medicinal Chemistry:**

* **Anti-inflammatory Activity:** 1,3-diphenyl-4-pyrazolecarbonitrile has been shown to exhibit anti-inflammatory activity in various studies. It can inhibit the production of inflammatory mediators like prostaglandins and leukotrienes, making it a potential lead compound for developing new anti-inflammatory drugs.
* **Antimicrobial Activity:** This compound has also been found to possess antimicrobial activity against certain bacteria and fungi, suggesting its potential use in developing new antibiotics or antifungal agents.
* **Anti-cancer Activity:** Research indicates that 1,3-diphenyl-4-pyrazolecarbonitrile might have anti-cancer activity by interfering with the growth and proliferation of cancer cells.
* **Other Potential Applications:** This compound has also been investigated for its potential as an analgesic (pain reliever), anticonvulsant, and anti-diabetic agent.

**2. Material Science:**

* **Luminescence:** 1,3-diphenyl-4-pyrazolecarbonitrile exhibits fluorescence properties, making it a potential candidate for applications in organic light-emitting diodes (OLEDs) and other optoelectronic devices.

**3. Organic Synthesis:**

* **Building Block:** 1,3-diphenyl-4-pyrazolecarbonitrile serves as a valuable building block for the synthesis of other complex organic molecules. Its nitrile group can be readily converted into various functional groups, allowing for the development of diverse derivatives with specific properties.

**Importance for Research:**

* **Lead Compound Development:** Due to its diverse biological activities, 1,3-diphenyl-4-pyrazolecarbonitrile is an attractive lead compound for the development of new drugs and therapies.
* **Structure-Activity Relationship Studies:** Researchers can use this compound as a template to investigate the structure-activity relationship of pyrazole derivatives. Modifying the structure of this molecule can lead to the discovery of new compounds with enhanced potency or selectivity for specific targets.
* **New Material Development:** The fluorescence property of this compound opens up possibilities for developing novel organic materials for optoelectronic devices and sensors.
* **Organic Chemistry Research:** 1,3-diphenyl-4-pyrazolecarbonitrile's synthetic versatility makes it a valuable tool for exploring new organic synthesis methods and reactions.

**Note:** Research on 1,3-diphenyl-4-pyrazolecarbonitrile is ongoing, and its full potential remains to be explored. While it shows promise in various fields, further investigations are necessary to validate its therapeutic and material science applications.

Cross-References

ID SourceID
PubMed CID700979
CHEMBL ID1536809
CHEBI ID121099

Synonyms (18)

Synonym
IFLAB1_001551
smr000060512
MLS000098769 ,
CHEBI:121099
HMS1416G11
AKOS001010375
1,3-diphenylpyrazole-4-carbonitrile
HMS2472O04
1,3-diphenyl-1h-pyrazole-4-carbonitrile
1h-pyrazole-4-carbonitrile, 1,3-diphenyl-
17647-21-1
cid_700979
1,3-diphenyl-4-pyrazolecarbonitrile
bdbm49022
CHEMBL1536809
Q27209342
DTXSID70351470
Z56813172
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
ring assemblyTwo or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved.
pyrazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency8.49210.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency0.31620.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency20.59620.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency8.91250.000811.382244.6684AID686978
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.01190.001318.074339.8107AID926; AID938
67.9K proteinVaccinia virusPotency20.38650.00018.4406100.0000AID720579; AID720580
gemininHomo sapiens (human)Potency0.06510.004611.374133.4983AID624297
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency35.48130.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]